Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post on X:
“MiNK Therapeutics featured Frontiers – Immunology, after:
- 2 Nature Oncogene Journal pubs
- Standout Ph2 data AACR -IO.
- Durable solid tumor responses
- No GvHD, No lymphodepletion, No HLA matching
- STTR grant to advance in GVHD
- Dual-function. Off-the-shelf. Ready to go.
More posts featuring MiNK Therapeutics.